Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Axim Biotechnologies (AXIM) Boosts Billion-Dollar Brand Portfolio with Launch of CanChew Plus™

Now that production of its next generation award-winning controlled-release cannabidiol (CBD) functional chewing gum, CanChew Plus™, has kicked off, Axim Biotechnologies (OTCQB: AXIM) has boosted its diverse billion-dollar product portfolio with another strong growth brand. With so many golden eggs in its brand basket, the company is expecting strong top line growth in the near future. Current revenue projections show AXIM could soon earn the rarified rank of unicorn.

AXIM is looking ahead to a bright future with an uplisting to either the NYSE or NASDAQ. The company’s strong sales projections are built on a number of factors. The company’s vertically-integrated supply chain speeds up logistics and reduces costs. It also facilitates full manufacturing capabilities at facilities in Almere in The Netherlands. AXIM has a healthy intellectual property (IP) portfolio that includes over 10 patents and over 20 trademarks, and the company has close to 20 products in various developmental stages.

AXIM’s product line is based on hemp, a cousin to marijuana classified under the same botanical category of cannabis sativa. The major difference between the two is that marijuana has significant amounts of tetrahydrocannabinol (THC) (5–20%), a psychotropic cannabinoid that will get you ‘high’. Hemp, on the other hand, has virtually no THC (less than 0.3%), but it is rich in cannabidiol (CBD) and cannabigerol (CBG).

Both CBD and CBG appear to offer benefits in treating some medical conditions. The AXIM product pipeline includes drug candidates to treat multiple sclerosis/pain spasticity, Parkinson’s disease, dementia, restless legs syndrome (RLS), Crohn’s disease, opioid addiction/cannabis dependence, tobacco smoking cessation, post-herpetic neuralgia, irritable bowel syndrome (IBS), inflammatory bowel disease, psoriasis/atopic dermatitis, glaucoma, and dry eye.

CanChew®, which contains 50 mg of hemp oil and 10 mg of CBD, is meant to alleviate IBS and inflammatory bowel disease. It is the world’s first patented controlled-release cannabinoid chewing gum. The new formulation, CanChew Plus™, contains the same active ingredients and is 60 percent smaller than the original CanChew® gums for an improved chewing experience. In addition, CanChew Plus™ offers an improved oral mucosal delivery system through microencapsulation that increases the bioavailability of the active ingredient from less than 50 percent, with CanChew®, to an absorption rate of 80 percent of CBD, after just 30 minutes of chewing.

In 2017, Axim plans to release CanChew® chewing gum as a food supplement. The company also intends to initiate a number of clinical studies for the product, including its evaluation in treating chronic pain and spasticity in patients with multiple sclerosis.

Currently trading at just under $10.00, the stock, under the symbol AXIM, peaked at $19.00 earlier this year. The folks at Motley Fool think it’s a good bet (, surmising that ‘investors were excited about the potential for Axim’s hemp-based chewing gum.’ They also called it ‘one of the best marijuana stocks this year’ in a 2016 report. Axim might just repeat that performance in 2017.

For more information, visit

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.